Search results below include Worst Pills, Best Pills Newsletter Articles where your
selected drug is a primary subject of discussion.
In this month’s news brief, we report on shortages of the inhaled asthma drug albuterol that have occurred because of the coronavirus pandemic.
Tremor is the single most common movement disorder, affecting millions of people in the U.S. If you have tremors, could one of your drugs be the cause? Read this article to learn the answer.
In this article, we provide a detailed update of the various drugs available for the long-term management of chronic obstructive pulmonary disease (COPD). Learn which drugs are safest for treating COPD and which ones we have designated as Do Not Use.
Asthma is a common disease afflicting more than 16 million American adults and 6 million children. Find out the safest and most effective options for managing this chronic lung disease.
If you or a loved one has chronic obstructive pulmonary disease (COPD), sometimes known as emphysema, and suffers from periodic acute COPD exacerbations requiring steroids, you should know that new research demonstrates that a five-day course of steroids for treating such exacerbations works just as well as a conventional 14-day course.
Commonly known as emphysema, chronic obstructive pulmonary disease (COPD) affects an estimated 24 million Americans, only half of whom are diagnosed. This article presents recent information regarding the use of drug treatments, including inhaled anti-inflammatory steroids, as well as important nondrug treatments that can be used as an adjunct to drug therapy.
The article reviews 12 prescription drugs, many of which are top-sellers, all of which are greatly overpriced in comparison to older "versions" of the same drugs. The patents on the old drugs expired so the "innovative" companies patented these new products, gaining a patent on them, and, for all practical purposes, using them as a license to print money. There is no evidence that any of the new ones are better than the now less-expensive, old versions.
With the imminent demise of CFC-propelled albuterol asthma inhalers and the substitution of HFA (hydroflouroalkane)as a more environmentally-friendly propellant, two sets of problems arise. First, and the main subject of this article, are differences between the old and new propellants that require special attention by asthmatics using the new HFA asthma inhalers because they may clog more easily than the older CFC-containing ones. The second problem is cost in that less expensive generic versions of the HFA inhalers will not be available until 2010 and the half-as-expensive generic CFC albuterol inhalers will not be manufactured or sold after December 31, 2008.
If you are presently using albuterol and your asthma is adequately controlled, there is no medical reason why you should be switched to levalbuterol. There is no convincing evidence that it is any safer or more effective than the older, much less expensive short-acting beta agonist, albuterol.
You should avoid these "new" single mirror images of old drugs, not out of concern about their safety or effectiveness, but because they are the same as the old drugs. In the long run, they cause economic harm both to individuals and to the health care system because they have come on the market with extended monopoly protection. Article lists some examples.